PROCEPT BioRobotics (PRCT) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

72OpportunityDD: Jul 24, 2026Analyst: 76

paidReference price

USD 17.6 (24/07/2026)

domainMkt cap

$998.93M

pie_chartShares

candlestick_chart52W

2026-07

trending_downShort interest

13.1%

MEDIUMNASDAQHealth Care888 employeesFounded 2007

Verdict: Favorable Risk/Reward —

Dislocation case: stock down 71% from 52W high and touching cycle low ($17.17) while FY26 revenue guide reaffirmed at +27-33% YoY and management targets positive adj. EBITDA in Q4 2026. Net cash $194M covers ~19% of market cap; a $10.5M insider open-market purchase (March 2026) plus $7.2M net insider buying in last 3 months signals conviction. Bear thesis (BofA/Truist/Leerink) is real — utilization deceleration and PAE competition — but is arguably now priced in below 2.5x forward sales vs peer median 3.5-5x. Binary Aug 4 earnings.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-24

PROCEPT BioRobotics Corporation (PRCT)

Medical Devices · NASDAQ · San Jose, CA

"Dislocated growth medtech: revenue compounding 25-35% into positive EBITDA, priced as if the multi-year story is broken."

Net cash $194M −71% from 52W high FY26 rev +27-33% guide Q4 2026 EBITDA target Insider buying $7.2M

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — EV/Revenue forward (peer-anchored), medtech growth profile

Fair value base case

USD 26.0

Range: USD 17.0-USD 42.0

Reference price: USD 17.6 (24/07/2026)

Base upside/downside: +48%

Primary method EV/Revenue forward with peer-derived multiple; secondary DCF cross-check confirms range. Implicit multiple 3.2x is within peer band. The bear case anchor of $13-14 vs current $17.55 = ~22% downside vs base upside +48% = asymmetry ratio 2.2x , consistent with the ASIM screening premise. Aug 4 earnings is a binary catalyst that will resolve much of the dispersion. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core capital + procedure business (EV)	$400M FY26E rev × 3.5x EV/Rev (peer-adjusted) = $1,400M EV / 56.92M sh	+24.60
Net cash	($246M cash − $52M debt) / 56.92M sh	+3.41
Consumables installed-base annuity	~1,200 systems × ~$25K/yr avg consumables × 3x = $90M / 56.92M sh (partial credit)	+0.80
WATER IV prostate cancer option	20% probability × $200M NPV expansion = $40M / 56.92M sh	+0.70
Expected dilution (equity comp)	~3% annual SBC creep × 1yr weight = −$1.5M / 56.92M sh	−0.50
Litigation reserve (Levi & Korsinsky class action)	Investigation stage — $30M expected exposure × 0.4 prob / 56.92M sh	−0.20
Reimbursement risk adjustment	CMS proposed physician fee schedule 2026: Cat I code assigned but ASP monitoring risk; −5% haircut on core	−2.80
FV base case	Sum of components above	≈ $26.00

Bull

$38–$45

Probability: 25%

Q2 beat + HYDROS utilization re-accelerates + WATER IV positive readout + strategic acquirer emerges (Boston Scientific / Medtronic / J&J MedTech). Re-rate to 5x forward FY27 rev ~$500M.

Base

USD 22.1-USD 29.9

Probability: 45%

Guidance delivered, Q4 EBITDA breakeven confirmed, PAE competition contained. Multiple normalizes to peer-median 3.5x forward as market shifts focus to FY27 revenue and margin expansion story.

Bear

$13–$17

Probability: 30%

Utilization deceleration worsens, PAE takes share materially, FY26 guide missed by 5-10%, EBITDA breakeven pushed to 2027. Multiple compresses to 2x forward. Class action liability crystallizes. Cash floor $3.41 + minimal business value ~$10 = $13-14.

Methodology: Primary method EV/Revenue forward with peer-derived multiple; secondary DCF cross-check confirms range. Implicit multiple 3.2x is within peer band. The bear case anchor of $13-14 vs current $17.55 = ~22% downside vs base upside +48% = asymmetry ratio 2.2x , consistent with the ASIM screening premise. Aug 4 earnings is a binary catalyst that will resolve much of the dispersion. ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: ASYMMETRY mode selection — PRCT chosen because it passes the asymmetry gate (hard floor via net cash + installed base + strategic value; upside via re-rating to peer median + M&A optionality). Classification is a selection filter only: the fair value below is derived independently from peer multiples and FY27 revenue trajectory.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

13.1%

~7.2M shares shorted on ~55M float. Elevated but not extreme; +13.5% YoY rise reflects bear thesis on utilization slowdown. Days-to-cover moderate.

🟡 Share dilution (1Y)

+3.5%

Shares out 55.0M → 56.9M. Normal SBC creep for growth medtech. No secondary equity raise announced; $246M cash covers ~4Y at current burn without dilution.

🔴 Buyback

No active repurchase program. Capital priority: fund international expansion + WATER IV trial. Rational given unprofitable stage, but signal weakness at current dislocation.

Short Interest — context

PRCT — 13.1%

13.1%

Insider signal (opposite direction): $10.5M open-market purchase by Rohit Desai (director) on 2026-03-09 and net $7.2M insider buying in last 3 months vs $509K selling. This is the strongest bullish insider print in company history and coincides with the dislocation. Class action investigation (Levi & Korsinsky, Frank R. Cruz) filed Mar 2026 — no material developments disclosed since; investigation stage only.

$Financial analysis — FY 2025-2026E

Revenue (TTM)

$322.0M

+29.3% YoY

Net loss (TTM)

−$102.5M

EBITDA margin improving Q1: −16% vs −91% Y/Y

Cash + investments

$246M

Net cash $194M, ~4Y runway

FY26E revenue

$390-410M

Reaffirmed guide (+27-33%)

Item	FY23	FY24	FY25	FY26E	Guidance
Revenue ($M)	133.4	224.5	308.0	390-410	+27-33%
Gross margin %	52%	60%	62%	65%+	Target 65%+
Adj. EBITDA ($M)	−79	−100	−90	−30 to −20	Q4 positive
Net loss ($M)	−79	−91	−96	−70 to −55	Trending better
U.S. procedures ('000)	15.7	28.3	44.5	60-64	+39-48% growth
Cash EOP ($M)	350	310	270	~225	Sufficient runway

Sources: 10-Q Q1 2026, FY25 10-K, GlobeNewswire earnings releases. FY26E from company guidance reaffirmed 2026-04-29.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	69.2	78.5	83.3	77.0	83.1
Gross margin %	58%	61%	63%	64%	65%
Net loss ($M)	−24.7	−22.8	−21.4	−26.7	−32.1
End-of-period cash ($M)	335	320	295	270	246

Financial position and sustainability

Cash runway (yrs at current burn)

~4.0y

FY26E revenue vs FY24 (2yr CAGR)

~34% CAGR

Gross margin expansion (FY23→FY26E)

+13pp

Short interest (% float)

13.1%

account_tree

Business model — AquaBeam & HYDROS surgical robotics for BPH and prostate cancer

One-platform urology robotics play

PROCEPT designs, manufactures and sells the AquaBeam and HYDROS Robotic Systems for image-guided waterjet ablation of prostate tissue (Aquablation therapy) — a minimally invasive alternative to TURP and laser enucleation for BPH. Model is capital-plus-consumable: ~$485K ASP per HYDROS system + $700-800 per-procedure single-use handpiece. FDA-cleared, category I CPT code assigned in 2026 physician fee schedule. Strong clinical body: WATER III RCT data (2026) upgraded Aquablation to a strong AUA and EAU guideline recommendation for BPH. WATER IV enrollment for prostate cancer indication completed May 2026 — potential $2B+ TAM expansion.

U.S. Capital + Procedures (BPH) ~$310-320M FY26E (~78% rev) 🟢 ramping Installed base ~950 U.S. systems by YE26. ASP up 14% QoQ to $485K driven by HYDROS mix. Utilization deceleration is the bear case pressure point. International expansion (BPH) ~$50-51M FY26E (~13% rev) 🟢 ramping HYDROS international launch March 2026. EAU 2026 strong recommendation is a major tailwind. UK, DE, JP focus. Structural growth runway 3-5y. Prostate cancer expansion (WATER IV) Pre-revenue, LT option 🟡 in trial Enrollment complete May 2026. FDA IDE expanded. Data readout 2027-2028. Success = doubles TAM. Not in base FV; +$0.70/sh option value.

gavel

Legal, regulatory and risk analysis

Utilization deceleration

High

Truist and Leerink both downgraded in June 2026 citing reduced confidence in procedure growth re-acceleration. If per-system procedures continue to decelerate, unit-economics thesis breaks. Q2 print will test this.

PAE (prostate artery embolization) competition

Moderate

Interventional radiology alternative gaining reimbursement traction; may steal share in lower-severity BPH patient pool. Clinical differentiation vs Aquablation not decisively established outside RCTs.

Securities class action investigation

Moderate

Levi & Korsinsky and Frank R. Cruz law firms opened investigations March 2026 following stock decline. Investigation-stage only, no complaint filed. Standard boilerplate for post-drop losses; probability of material settlement low. Reserved $0.20/sh.

CEO transition execution

Moderate

Founder-CEO Reza Zadno retired July 2025, replaced by Larry Wood. Wood led commercial realignment in H1 2026 with launch teams targeting utilization. Execution risk exists but early results (Q1 gross margin 65%, ASP +14% QoQ) show discipline.

CMS reimbursement risk

Low

Aquablation received Category I CPT code in 2026 CMS proposed physician fee schedule — meaningful upgrade from prior Cat III. Reimbursement pathway stable. Ongoing ASP monitoring but no active downside pressure.

Net cash floor

Positive

$246M cash − $52M debt = $194M net cash ($3.41/share). ~4 years runway at current burn without any incremental revenue. Removes going-concern risk entirely and provides genuine floor for bear scenario.

Insider conviction signal

Positive

Director R. Desai purchased $10.5M in open market Mar 2026 at higher prices. Net insider buying $7.2M vs $509K selling last 3 months. Strongest bullish insider print in company history. Suggests governance sees value below current levels.

Strategic M&A optionality

Positive

Sub-$1B market cap growth medtech with FDA-cleared single-product platform and defensible IP is exactly the profile Boston Scientific, Medtronic, J&J MedTech, and Stryker have historically acquired at 5-8x forward sales (e.g. Axonics acquisition at ~10x by Boston Scientific 2024).

article

SWOT analysis

Strengths

+FDA-cleared single-product platform with Category I CPT reimbursement
+AUA and EAU strong guideline recommendation for BPH treatment
+Net cash $194M ($3.41/sh) provides ~4y runway — no dilution risk near-term
+Revenue +29-37% YoY; gross margin expanding from 52% to 65%+ target
+Insider buying pattern historic in scale ($10.5M open-market purchase)

Weaknesses

−Persistent net losses; positive adj. EBITDA target only Q4 2026
−Single-product concentration: HYDROS is the entire near-term thesis
−Utilization per system decelerating — bears' central concern
−Analyst downgrades from Buy to Hold (Truist, Leerink) in June 2026
−No buyback program despite stock at cycle low

Opportunities

→International HYDROS ramp: $50M FY26E → potential $150M+ FY28
→WATER IV prostate cancer indication — TAM expansion 2027-2028
→Multiple re-rating from 2.5x forward to 3.5-4.5x peer median
→Strategic acquirer (BSX/MDT/JNJ/SYK) at 5-8x forward sales premium
→Aug 4 earnings could resolve bear thesis quickly if utilization stabilizes

Threats

!PAE competition erodes BPH share among interventional radiologists
!Laser enucleation (HoLEP) alternative with lower capex requirement
!CMS ASP monitoring may compress reimbursement over medium term
!Class action escalation from investigation to filed complaint
!Q2 miss + guide cut = downside acceleration to bear case $13-14

article

Summary by assessment area

🟢 Financial risk — Low

Net cash $194M, ~4y runway
Debt trivial ($52M vs $246M cash)
Path to positive EBITDA Q4 2026

🟡 Business risk — Moderate

Utilization deceleration is real
Single-product concentration high
Growth still +29% TTM offsets concerns

🔵 Risk/reward — Favorable

Base upside +48% vs downside −22%
Asymmetry ratio ~2.2x
Binary Aug 4 catalyst resolves dispersion

2026-08-04 earnings

Q2 2026 Earnings Release

short-term Impact: High Direction: Binary

First real test of Larry Wood's commercial realignment. Utilization per system is the number to watch. Beat + reaffirmed guide could catalyze multiple re-rating from 2.5x to 3.5x forward sales. Miss accelerates downside to bear-case $13-14 anchor.

2026-08-04 guidance

FY26 revenue & EBITDA guidance refresh

short-term Impact: High Direction: Binary

Current guide: $390-410M revenue, Q4 positive adj. EBITDA. Reiteration = bullish; narrowed to low end = neutral; cut = bear-case trigger. EBITDA breakeven confirmation is the key financial milestone.

2026-10-15 strategic

2026 Investor Day — multi-year financial framework

medium-term Impact: High Direction: Bullish

First formal multi-year framework under new CEO Wood. Expected: FY28-30 revenue trajectory, steady-state EBITDA margin target, international ramp cadence. Historically re-rates growth medtech names +15-25%.

2027-06-30 product

WATER IV RCT topline data — prostate cancer

long-term Impact: High Direction: Binary

Enrollment complete May 2026. Positive data doubles addressable TAM (BPH → BPH + prostate cancer) and moves the WATER IV option from $0.70/sh to $4-6/sh. Miss = leaves company as single-indication BPH play.

2026-11-04 earnings

Q3 2026 Earnings Release

medium-term Impact: High Direction: Binary

Final quarter before targeted Q4 positive EBITDA. Utilization trend confirmation critical. Strong Q3 execution + Investor Day framework = compound catalyst for re-rating into year-end.

2027-02-25 operational

Q4 2026 adj. EBITDA breakeven confirmation

long-term Impact: High Direction: Bullish

FY25 print typically reveals Q4 EBITDA. Confirming positive adj. EBITDA removes the "unprofitable medtech" penalty and unlocks profitable growth valuation multiples (4-5x forward sales range).

2026-12-31 ma

Strategic acquirer optionality (BSX/MDT/JNJ/SYK)

medium-term Impact: High Direction: Bullish

Sub-$1B growth medtech with FDA-cleared single-product platform is exactly the profile large medtech acquirers target. Precedent: BSX acquired Axonics at ~10x forward sales in 2024. Not datable but probability meaningfully non-zero at current valuation.

2026-09-30 regulatory

Class action investigation resolution

medium-term Impact: Medium Direction: Bearish

Levi & Korsinsky and Frank R. Cruz investigations opened March 2026. Decision to file (or drop) complaint typically comes within 6-9 months. Filed complaint = ~$20-40M expected reserve; dropped = removes overhang.

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "PRCT tratta a −71% dai massimi con floor cassa di $3.41/az. e guidance FY26 riaffermata a +27-33% ricavi. Asimmetria 2.2x (upside base +48% vs downside −22%). Aug 4 earnings è il catalizzatore binary.", "en": "PRCT is at −71% from 52W high with $3.41/sh cash floor and FY26 revenue guide reaffirmed at +27-33%. Asymmetry ratio 2.2x (base upside +48% vs downside −22%). Aug 4 earnings is the binary catalyst."}, "bull_points": [ {"it": "Net cash $194M copre 19% market cap, ~4y runway senza diluzione", "en": "Net cash $194M covers 19% of market cap, ~4y runway without dilution"}, {"it": "Insider buying storico: $10.5M open-market Mar 2026 + $7.2M netti in 3 mesi", "en": "Historic insider buying: $10.5M open-market Mar 2026 + $7.2M net in 3 months"}, {"it": "Trade 2.5x P/S fw vs peer median 3.5x — sconto 28% con crescita superiore", "en": "Trades at 2.5x forward P/S vs peer median 3.5x — 28% discount despite superior growth"} ], "bear_points": [ {"it": "Utilization per sistema in decelerazione — bear thesis principale", "en": "Per-system utilization decelerating — the core bear thesis"}, {"it": "Truist e Leerink hanno declassato a Hold citando reimbursement + PAE", "en": "Truist and Leerink downgraded to Hold citing reimbursement + PAE competition"}, {"it": "Adj. EBITDA positivo target solo Q4 2026 — 2 trimestri di execution", "en": "Positive adj. EBITDA only targeted for Q4 2026 — two quarters of execution risk"} ], "risks": [ {"it": "Miss + guide cut ai Q2 earnings = downside a $13-14 (bear case)", "en": "Miss + guide cut at Q2 earnings = downside to $13-14 (bear case)"}, {"it": "Class action investigation Mar 2026 può evolvere in complaint filed", "en": "Class action investigation from Mar 2026 may escalate to filed complaint"}, {"it": "Concorrenza PAE (prostate artery embolization) può erodere share BPH", "en": "PAE (prostate artery embolization) competition may erode BPH market share"} ] }

Sources & Disclaimer

Sources: StockAnalysis.com PRCT overview (close 2026-07-23 $17.55); CoinCodex PRCT quote; Trefis 52-week-low list 2026-07-23; PROCEPT BioRobotics Q1 2026 earnings release (GlobeNewswire 2026-04-29); Truist / Leerink / Piper Sandler / Evercore ISI analyst notes June-July 2026; SEC 10-Q Q1 2026; Fintel / Nasdaq short interest 2026-07; Alpha Spread / TipRanks insider transactions 2026-Q1-Q2; AUA / EAU guideline announcements 2026. Market data — last verified close 2026-07-23: PRCT $17.55, market cap $998.93M, shares out 56.92M, 52W range $17.17–$60.57. Short interest 13.1% of float. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.